Browse studies

Find your next paid study

35 recruiting studies matching your filters

Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell Lymphomas

This phase I trial tests the safety, side effects and best dose of ruxolitinib in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP…

Follicular Helper T-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeFollicular Helper T-Cell Lymphoma, Follicular-Type+3 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07278856

The T-cell Lymphoma Master Repository (TCLMR): A Prospective Databank of Patients With T-cell Lymphoma With Clinical Annotation and Matched Tumor Specimens

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the infor…

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+28 more

Phase 1

MC1684 Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolum…

B-Cell Non-Hodgkin LymphomaHistiocytic and Dendritic Cell NeoplasmMyelodysplastic Syndrome+16 more

Estimated

Phase 1

A Phase Ib Trial Combining Bexarotene With Ultra-Low Dose Total Skin Electron Beam (Tseb) Radiotherapy For The Treatment Of Diffuse Cutaneous T-Cell Lymphomas

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis …

Cutaneous T-cell Lymphoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05296304

Phase 1

A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

T-cell LymphomaCutaneous/Peripheral T-Cell LymphomaPeripheral T-cell Lymphoma+8 more

Estimated

~$10 – $8,750

SciTech Development, Inc.NCT04234048

Phase 2

Phase II Study of Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant in T-Cell Lymphoma

This phase II trial tests how well ruxolitinib as a maintenance medication works to prevent relapse and graft-versus-host disease (GVHD) for patients who have …

T-cell LymphomaGraft Versus Host DiseaseLymphoma, T-Cell+5 more

Estimated

~$10 – $7,500

Jonathan BrammerNCT07356245

Phase 1

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more

Peripheral Blood, Urine and Skin Sample Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future researc…

Cutaneous T-cell LymphomaSezary SyndromeMycosis Fungoides+2 more

Estimated

~$10 – $750

University of PittsburghNCT00177268

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell P…

Peripheral T-Cell Lymphoma

Estimated

~$10 – $1,125

Associazione Angela Serra per la ricerca sul cancroNCT03964480

Phase 2

Phase II Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Single-arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) or CHOEP in patien…

T Cell LymphomaT-cell Lymphoma

Estimated

~$10 – $6,250

Yale UniversityNCT05996185

Phase 2

A Phase II Trial of JAK Inhibitor Added to Immunotherapy for Treatment of Relapsed/Refractory T-cell Lymphoma and 9p Amplified Lymphomas

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractor…

Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more

Estimated

~$10 – $7,500

Seda S. ToluNCT07283822